Evidence map›Paper›PMID 34721512›Full record

ArticleLiver cancer2021

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.

Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron, Stephen L Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J Lim and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arndt VogelDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Catherine FrenetteDepartment of Transplantation Hepatology, Scripps MD Anderson Cancer Center, La Jolla, California, USA.
Max SungDepartment of Hematology-Oncology, Tisch Cancer Institute at Mount Sinai, New York, New York, USA.
Bruno DanieleDepartment of Oncology, Ospedale del Mare, Napoli, Italy.
Ari BaronDepartment of Clinical Oncology, Pacific Hematology Oncology Associates, San Francisco, California, USA.
Stephen L ChanDepartment of Clinical Oncology, The State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China.
Jean Frédéric BlancDepartment of Clinical Research and Innovation, University Hospital of Bordeaux, Bordeaux, France.
Toshiyuki TamaiEisai Co., Ltd., Tokyo, Japan.
Min RenEisai Inc., Biostatistics, Oncology Business Group, Woodcliff Lake, New Jersey, USA.
Howard J LimDepartment of Medicine, British Columbia Cancer, Vancouver, British Columbia, Canada.
Daniel H PalmerDepartment of Medical Oncology, Liverpool Experimental Cancer Medicine Centre, University of Liverpool, Liverpool, United Kingdom.
Yuko TakamiDepartment of Hepato-Biliary-Pancreatic Surgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute, Fukuoka, Japan.
Masatoshi KudoDepartment of Medicine, Kindai University Faculty of Medicine, Osakasayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBaseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFLECT study examined the efficacy and safety outcomes for lenvatinib and for sorafenib in patients with uHCC, assessed by Child-Pugh score (CPS) and albumin-bilirubin (ALBI) grade.

methodsEfficacy and safety were assessed in patient cohorts from REFLECT according to study entry baseline ALBI grade and CPS.

resultsLenvatinib treatment generally provided survival benefits in all groups. Median overall survival (OS) among patients with an ALBI grade of 1 was consistently higher than among patients with an ALBI grade of 2 for both the lenvatinib and sorafenib arms (lenvatinib: 17.4 vs. 8.6 months; sorafenib: 14.6 vs. 7.7 months, respectively). Median OS among patients with a CPS of 5 was consistently higher than among patients with a CPS of 6 (lenvatinib: 15.3 vs. 9.4 months; sorafenib: 14.2 vs. 7.9 months, respectively). Progression-free survival and objective response rates for these ALBI grades and CPS demonstrated similar patterns. Among patients who received lenvatinib and experienced a treatment-related treatment-emergent adverse event leading to withdrawal, 6.6% had an ALBI grade of 1, while 13.3% had an ALBI grade of 2, and 7.9% had a CPS of 5, while 12.1% had a CPS of 6.

conclusionsBetter liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.

Indexed as

Albumin-bilirubin gradeChild-Pugh scoreLenvatinibSorafenib

Identifiers

PMID34721512
PMCPMC8527908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.